<img alt="" src="https://secure.agile-company-247.com/261975.png" style="display:none;">

 Longevity Leaders Logo White



15-16 March 2023
Congress Center Basel

Can't wait till March? Join us in October in Boston.
Find out more



Created by    LSX

A new paradigm for disease prevention

RNA medicines are at a critical moment in time. mRNA vaccines dominate the headlines in the wake of the COVID-19 pandemic. But huge advances are also being made in RNAi and antisense technologies. Our understanding of RNA chemistry continues to mature. Delivery tools are increasingly sophisticated and impactful. Advances in genomics and gene editing are driving new approaches. And exciting work targeting RNA with small molecules is emerging.

With that in mind, we can’t wait to bring the community together, face-to-face, for the second annual RNA Leaders Europe Congress.

So, if you’re passionate about all things RNA do join us, and more than 600 biotech, pharmaceutical, investment, regulatory and scientific professionals at the RNA Leaders Europe Congress. You’ll hear the latest advances in RNA chemistry, get clinical updates from the companies developing new therapies and source the services partners who are helping to deliver drugs to patients.

RNA Leaders World Congress

Meet the 2022 speakers

Douglas Fambrough, CEO, Dicerna Pharmaceuticals

Douglas Fambrough

Dicerna Pharmaceuticals
Melissa Moore, CSO, Moderna

Melissa Moore

Angele Maki, SVP, Business Development, ReCode Therapeutics

Angele Maki

SVP, Business Development
ReCode Therapeutics
Sylke Poehling, Senior Vice President and Global Head, Therapeutic Modalities, Roche

Sylke Poehling

Senior Vice President and Global Head
Therapeutic ModalitiesRoche
Shalini Andersson, Chief Scientist, New Therapeutic Modalities and Head of Oligonucleotide Discovery, AstraZeneca

Shalini Andersson

Chief Scientist, New Therapeutic Modalities & Head of Oligonucleotide Discovery
Denis Drygin, CSO, Regulus Therapeutics

Denis Drygin

Regulus Therapeutics
Huw Nash, COO and CBO, Stoke Therapeutics-1

Huw Nash,

Stoke Therapeutics
Matthew Wood, Professor of Neuroscience and Deputy Head, Medical Sciences Division, University of Oxford

Matthew Wood

Professor of Neuroscience and Deputy Head, Medical Sciences Division
University of Oxford
Laura Sepp-Lorenzino, CSO, Intellia Therapeutics

Laura Sepp-Lorenzino

Intellia Therapeutics
Howard Stern, CSO, Korro Bio

Howard Stern

Korro Bio
David Slack CEO, Cend Therapeutics

David Slack

Cend Therapeutics
Sudha Chivukula, Head of RNA Technology, Research & External Innovation, Sanofi Pasteur

Sudha Chivukula

Head of RNA Technology, Research & External Innovation
Sanofi Pasteur
Tamar Grossman Global Head of RNA and Targeted Therapeutics, Janssen

Tamar Grossman

Global Head of RNA and Targeted Therapeutics
Peter Smith, Co-Founder, President and CEO, Remix Therapeutics

Peter Smith

Co-Founder, President and CEO
Remix Therapeutics
Bill Haney, CEO & Chairman, Skyhawk Therapeutics

Bill Haney

CEO & Chairman
Skyhawk Therapeutics
Malgorzata Gonciarz, Associate Vice President, Genetic Medicine, Eli Lilly

Malgorzata Gonciarz

Associate Vice President, Genetic Medicine
Eli Lilly


What Our Attendees Say

Platinum partners


Chemgenes logo


Precision Nanosystems

Gold partners

AGC Biologics logo


Axolabs 300x

Catalent logo


Codex DNA

EuroAPI logo

Evonik 300x

Roche 300x

Silver partners

Eclipse Bioinnovations

Bronze partners

ArcticZymes logo

NanoVation Therapeutics Logo


PolyPeptide Group


Zymo Research logo-1

What will you learn?

  • How the RNA field has accelerated in the past two years, including major scientific and clinical developments
  • New advancements in systemic and topical delivery platforms and their applications
  • How computational biology is advancing RNA drug discovery including new tools for target, mechanism and molecule discovery
  • Latest pre-clinical updates spanning mRNA, RNAi, antisense and targeting RNA with small molecules
  • Application of gene therapy and RNA editing approaches


500+ companies actively developing RNA therapeutics

4000+ live clinical trials for RNA therapeutics and vaccines

2 major mRNA vaccine approvals in 2020

3 RNAi therapeutic approvals in the past 4 years

1500+ investors actively looking to fund RNA technology

96 successful fund raises by mid 2021 (vs 101 total in 2020)

More than $1.65bn raised by RNA biotech mid 2021

Millions of lives saved by mRNA vaccines to date

Become a partner

Do you offer products or services to support RNA drug development? The pharma and biotech executives attending RNA Leaders World Congress want to meet you! They are looking for:

    • Delivery platforms
    • Contract research
    • Equipment supply
    • Target discovery tools
    • CDMO and CMC
    • Reagent providers
    • RNA editing tools
    • RNA analysis
    • Legal services